Regulatory impact statement
Publication Date:
20 February 2024
The Government’s 100-day plan includes a commitment to “allow the sale of cold medication containing pseudoephedrine”. This regulatory impact statement sets out analysis of issues relating to the proposed changes, including amendments to the Misuse of Drugs Act 1975 and the Medicines Regulations 1984 to reclassify pseudoephedrine from a Class B2 controlled drug to a Class C3. This would enable pseudoephedrine medicines for the symptoms of cold and flu to be sold in pharmacies without a prescription.